Vet Med - Czech, 2017, 62(5):261-268 | DOI: 10.17221/130/2015-VETMED

The effect of orally administered Budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel diseaseOriginal Paper

A. Rychlik*, M. Nowicki, A. Kolodziejska-Sawerska, M. Szweda
Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland

The aim of this study was to evaluate the effect of Budesonide on the hypothalamic-pituitary-adrenal (HPA) axis in dogs with inflammatory bowel disease. The effect of orally administered Budesonide (Entocort) on the HPA axis was analysed in 21 dogs with inflammatory bowel disease. Biochemical analyses were carried out to evaluate the activity levels of alanine aminotransferase, asparagine aminotransferase, alkaline phosphatase, cortisol and endogenous adrenocorticotropic hormone. Urine samples were collected from each patient before the study and after 30 days of the experiment to determine the composition and the physical and chemical properties of urine sediments. Considerably lower serum concentrations of cortisol and endogenous adrenocorticotropic hormone were observed after 30 days of treatment. A significant increase in alkaline phosphatase levels was noted on Day 30. In the studied dogs, the drop in HPA axis activity was correlated with side effects associated with the administered glucocorticosteroid (polyuria, polydipsia). In conclusion, we have shown that oral administration of Budesonide to dogs diagnosed with inflammatory bowel disease significantly suppressed the activity of the HPA axis.

Keywords: glucocorticosteroids; IBD treatment; eACTH concentration; side effects; HPA axis

Published: May 31, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlik A, Nowicki M, Kolodziejska-Sawerska A, Szweda M. The effect of orally administered Budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. Vet Med - Czech. 2017;62(5):261-268. doi: 10.17221/130/2015-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angelucci E, Malesci A, Danese S (2008): Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Current Medicinal Chemistry 15, 2527-2535. Go to original source... Go to PubMed...
    2. Badylak SF, Van Vleet JF (1981): Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy. American Journal of Veterinary Research 42, 1310-1318.
    3. Brattsand R (1990): Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Journal of Gastroenterology and Hepatology 4, 407-414. Go to original source...
    4. Brattsand R, Miller-Larsson A (2003): The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clinical Therapeutics 25, 28-41. Go to original source... Go to PubMed...
    5. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG, Global Budesonide Study Group (1997): Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 41, 209-214. Go to original source... Go to PubMed...
    6. Craven M, Simpson JW, Ridyard AE, Chandler ML (2004): Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). Journal of Small Animal Practice 45, 336-342. Go to original source... Go to PubMed...
    7. Day MJ, Blizer T, Mansell J, Wilcock B, Hall EJ, Jergens A, Minami T, Willard M, Washabau R (2008): Histopathological standards for the diagnosis of gastrointestinal inflammation in endoscopic biopsy samples from the dog and cat: a report from the World Small Animal Veterinary Association Gastrointestinal Standarization Group. Journal of Comparative Pathology 138, 1-43. Go to original source... Go to PubMed...
    8. DeNovo RC, Prasse KW (1983): Comparison of serum biochemical and hepatic functional alterations in dogs treated with corticosteroids and hepatic duct ligation. American Journal of Veterinary Research 44, 1703-1709.
    9. Dillon AR, Sorjonen DC, Powers RD, Spano S (1983): Effects of dexamethasone and surgical hypotension on hepatic morphologic features and enzymes of dogs. American Journal of Veterinary Research 44, 1996-1999.
    10. Dillon AR, Spano JS, Powers RD (1980): Prednisolone-induced hematologic, biochemical and histologic changes in the dog. Journal of the American Animal Hospital Association 16, 831-837.
    11. Edsbacker S, Andersson T (2004): Pharmacokinetics of budesonide (EntocortEC) capsules for Crohn's disease. Clinical Pharmacokinetics 43, 803-821. Go to original source... Go to PubMed...
    12. Garcia-Sancho M, Rodriguez-Franco F, Sainz A, Mancho C, Rodriguez A (2007): Evaluation of clinical, macroscopic and histopathologic response to treatment in nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis. Journal of Veterinary Internal Medicine 21, 11-17. Go to original source...
    13. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T (1994): Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. New England Journal of Medicine 331, 836-841. Go to original source... Go to PubMed...
    14. Jergens AE, Simpson KW (2012): Inflammatory bowel disease in veterinary medicine. Frontiers in Bioscience (Elite Edition) 4, 1404-1419. Go to original source... Go to PubMed...
    15. Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R (2003): A scoring index for disease activity in canine inflammatory bowel disease. Journal of Veterinary Internal Medicine 17, 291-297. Go to original source... Go to PubMed...
    16. Jonsson G, Astrom A, Andersson P (1995): Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metabolism and Disposition 23, 137-142.
    17. Lundin PD, Edsbacker S, Bergstrand M, Ejderhamn J, Linander H, Hogberg L, Persson T, Escher JC, Lindquist B (2003): Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Alimentary Pharmacology and Therapeutics 17, 85-92. Go to original source... Go to PubMed...
    18. Malewska K, Rychlik A, Nieradka R, Kander M (2011): Treatment of inflammatory bowel disease (IBD) in dogs and cats. Polish Journal of Veterinary Sciences 14, 165- 171. Go to original source... Go to PubMed...
    19. Meyer DJ (1982): Prolonged liver test abnormalities and adrenocortical suppression in a dog following a single intramuscular glucocorticoid dose. Journal of the American Animal Hospital Association 18, 725-727.
    20. Meyer DJ, Moriello KA, Feder BM, Fehrer-Sawyer SL, Maxwell AK (1990): Effect of otic medications containing glucocorticoids on liver function test results in healthy dogs. Journal of the American Veterinary Medical Association 196, 743-744. Go to original source...
    21. Miller-Larsson A, Gustafsson B, Persson CG, Brattsand R (2001): Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. Alimentary Pharmacology and Therapeutics 15, 2019-2025. Go to original source... Go to PubMed...
    22. Raff H (1987): Glucocorticoid inhibition of neurohypophysial vasopressin secretion. American Journal of Physiology 252, 635-644. Go to original source... Go to PubMed...
    23. Rutgers HC, Batt RM, Vaillant C, Riley JE (1995): Subcellular pathologic features of glucocorticoid-induced hepatopathy in dogs. American Journal of Veterinary Research 56, 898-907. Go to original source...
    24. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P (1992): The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. New England Journal of Medicine 326, 226-230. Go to original source... Go to PubMed...
    25. Simpson KW, Jergens AE (2011): Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Veterinary Clinics: Small Animal Practice 41, 381-398. Go to original source... Go to PubMed...
    26. Spencer CM, McTavish D (1995): Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50, 854-872. Go to original source... Go to PubMed...
    27. Stroup ST, Behrend EN, Kemppainen RJ, Smith-Carr S (2006): Effects of oral administration of controlled-ilealrelease budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. American Journal of Veterinary Research 67, 1173-1178. Go to original source... Go to PubMed...
    28. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E (1998): A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. The New England Journal of Medicine 339, 370-374. Go to original source... Go to PubMed...
    29. Tumulty JW, Broussard JD, Steiner JM, Peterson ME, Williams DA (2004): Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. Journal of the American Animal Hospital Association 40, 120-123. Go to original source... Go to PubMed...
    30. Washabau RJ (2008): Summary of findings and reports of the WSAVA Gastrointestinal Standardization Group. The 33rd WSAVA Congress, Dublin. August 20-24, 2008. 60-62.
    31. Zareie M, Brattsand R, Sherman PM, McKay DM, Perdue MH (1999): Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. Journal of Pharmacology and Experimental Therapeutics 289, 1245-1249.

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content